Zevra Therapeutics (ZVRA) stock price is $10.47, up 3.05% on the day, as of Oct 20, 2026. It has a market cap of $619.95Mn and a P/E ratio of 10.64, and is classified in the Pharmaceuticals industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap619.95 Mn
P/E10.64
P/S4.55
Div. Yield0.00
Revenue Growth (1y) (Qtr)53.28
Add ratio to table…
About
Zevra Therapeutics Inc is a commercial-stage company focused on bringing life-changing therapies to people living with rare diseases. The company is committed to expanding patient access progressing its pipeline toward key milestones and delivering meaningful therapeutics. Zevra Therapeutics Inc operates through disciplined execution of its strategic plan guided by core values including patient centricity integrity accountability innovation and courage. The company has built…
Zevra Therapeutics Inc is a commercial-stage company focused on bringing life-changing therapies to people living with rare diseases. The company is committed to expanding patient access progressing its pipeline toward key milestones and delivering meaningful therapeutics. Zevra Therapeutics Inc operates through disciplined execution of its strategic plan guided by core values including patient centricity integrity accountability innovation and courage. The company has built a diverse portfolio of products and product candidates through internal development and strategic investments via acquisition. Zevra Therapeutics Inc is transforming into a leading rare-disease company by prioritizing the commercialization and global expansion of its lead product MIPLYFFA while maintaining OLPRUVA as commercially available and advancing the development of its clinical stage asset celiprolol.
Zevra Therapeutics Inc generates revenue primarily from the sale of its approved commercial products MIPLYFFA and OLPRUVA as well as through royalty and milestone payments from partnered products such as AZSTARYS. The company receives quarterly tiered royalty payments based on a percentage of net sales from its collaboration and license agreement with Commave for AZSTARYS. Zevra Therapeutics Inc also earns revenue from the sale of OLPRUVA in the United States which it began generating in the fourth quarter of 2023. The company does not currently generate revenue from MIPLYFFA in the United States as it received FDA approval in September 2024 and became commercially available for dispense in November 2024 with commercial ramp-up underway. Revenue is derived from selling therapies to patients suffering from rare diseases including Niemann-Pick disease type C urea cycle disorders and vascular Ehlers-Danlos syndrome through specialty pharmacy distribution channels and arrangements with third parties for marketing sales medical affairs distribution and other non-technical capabilities.
The company operates through the following segments: MIPLYFFA OLPRUVA Celiprolol KP1077 and AZSTARYS.
MIPLYFFA is an orally-delivered treatment for Niemann-Pick disease type C indicated for use in combination with miglustat for the treatment of neurological manifestations in adult and pediatric patients two years of age and older. It received FDA approval in September 2024 and became commercially available in the United States in November 2024. Zevra Therapeutics Inc holds global rights to develop and commercialize MIPLYFFA and has filed a Marketing Authorization Application with the European Medicines Agency which is currently under review. The product is also being made available to patients in France Germany and other EU member states through an expanded access program.
OLPRUVA is a proprietary and novel formulation of sodium phenylbutyrate powder packaged in pre-measured single-dose envelopes approved in the United States as adjunctive therapy to standard of care for the chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase ornithine transcarbamylase or argininosuccinic acid synthetase. Zevra Therapeutics Inc began generating revenue from OLPRUVA sales in the United States in the fourth quarter of 2023 and has a partnership with Relief Therapeutics SA which holds exclusive development and commercialization rights for OLPRUVA in Geographical Europe.
Celiprolol is an investigational product candidate being advanced for the treatment of Vascular Ehlers-Danlos syndrome in patients with a confirmed type III collagen mutation. Zevra Therapeutics Inc is actively enrolling a Phase 3 clinical trial known as DiSCOVER to determine whether celiprolol reduces the risk of clinical events in patients with VEDS. The drug has received Orphan Drug designation and Breakthrough Therapy designation from the FDA and is generally protected by U. S. patents with expiration potential through 2038.
KP1077 utilizes serdexmethylphenidate a proprietary prodrug of d-methylphenidate as its active pharmaceutical ingredient and is being developed and evaluated for the treatment of Idiopathic Hypersomnia and narcolepsy. Zevra Therapeutics Inc completed a Phase 2 clinical trial for KP1077 in March 2024 which provided meaningful information on optimal dose and dosing regimen to inform Phase 3 trial design. The product has been granted orphan drug designation by the FDA for the treatment of Idiopathic Hypersomnia.
AZSTARYS contains d-MPH and serdexmethylphenidate and is approved by the FDA as a once-daily treatment for attention deficit hyperactivity disorder in patients age six years and older. Zevra Therapeutics Inc markets AZSTARYS in the United States under a collaboration and license agreement with Commave under which it receives quarterly tiered royalty payments based on net sales and milestone payments. Corium an affiliate of Commave leads all commercialization activities for AZSTARYS in the United States.
Zevra Therapeutics Inc operates in the rare disease therapeutics industry where it faces competition from other pharmaceutical and biotechnology companies developing treatments for similar indications. For MIPLYFFA the company competes with AQNEURSA approved by IntraBio Inc for the treatment of neurological manifestations of Niemann-Pick disease type C. For OLPRUVA the company competes against branded and generic forms of phenylbutyrate including RAVICTI marketed by Amgen Inc and PHEBURANE marketed by Medunik USA. For celiprolol there are currently no approved therapies anywhere in the world for Vascular Ehlers-Danlos syndrome though the drug has become standard of care in some European countries when prescribed off label. For KP1077 the company anticipates competition from XYWAV marketed by Jazz Pharmaceuticals and other products in development for Idiopathic Hypersomnia. For AZSTARYS the company competes against currently marketed branded and generic methylphenidate products for ADHD including CONCERTA QUELBREE QUILLIVANT XR QUILLICHEW ER RITALIN FOCALIN FOCALIN XR METADATE CD DAYTRANA CONTEMPLA XR-ODT JORNAY PM and ADHANSIA XR. Zevra Therapeutics Inc differentiates itself through its focus on rare diseases with limited or no treatment options its proprietary Ligand Activated Technology platform and its strategic acquisitions that have expanded its pipeline and commercial footprint.
Zevra Therapeutics Inc serves patients diagnosed with rare diseases including Niemann-Pick disease type C urea cycle disorders vascular Ehlers-Danlos syndrome Idiopathic Hypersomnia narcolepsy and attention deficit hyperactivity disorder. The company works with prescribing clinicians healthcare providers and specialty pharmacy distributors to reach its patient base. Zevra Therapeutics Inc has established promotional programs such as Quick Start a thirty-day free trial program and patient co-pay programs to drive awareness and ensure access to its therapies. The company does not disclose specific customer names such as individual hospitals or healthcare organizations in the filing but serves patients through arrangements with third-party distributors and specialty pharmacy providers for the sale of its approved products.
Sector:HealthcareSector rationaleZevra Therapeutics is a commercial-stage pharmaceutical company that develops and sells therapies for rare diseases, such as MIPLYFFA for Niemann-Pick disease type C and OLPRUVA for urea cycle disorders. Its revenue is derived from the sale of these medical products and royalty payments from partnered pharmaceutical products like AZSTARYS, fitting squarely within the Pharmaceuticals and Biotechnology industries of the Healthcare sector.Industries:PharmaceuticalsPharmaceuticalsPrimaryZevra Therapeutics develops and markets branded prescription drugs for rare diseases, specifically MIPLYFFA for Niemann-Pick disease type C and OLPRUVA for urea cycle disorders. Its revenue is derived from the sale of these branded pharmaceutical products through specialty pharmacy distribution channels.BiotechnologyBiotechnologySecondaryThe company utilizes a proprietary Ligand Activated Technology platform and develops clinical-stage assets like celiprolol and KP1077, which are characteristic of biotechnology-driven drug discovery and development.Classified using BQ-MICSCIK: 0001434647
Bull & bear
Investment Thesis
▲ Bull case
ZVRA's MyPlifer has demonstrated a clear path to capturing the majority of the addressable NPC patient population in the U.S., with 170 prescription enrollment forms received since launch representing approximately half of the estimated 900 U.S. patients, and the company is actively expanding beyond traditional centers of excellence into community-based prescribers through its AI-driven targeting model and disease awareness campaigns, which is lowering barriers to diagnosis in an underdiagnosed disease where heterogeneity often delays identification; this strategy is already yielding new enrollments from both previously undiagnosed and newly diagnosed patients, as evidenced by the nine enrollment forms in Q1 alone, suggesting sustainable patient acquisition momentum that could drive MyPlifer U.S. net sales well beyond the current $24.6 million quarterly run rate as diagnosis rates improve and the combination therapy benefit with miglustat gains broader acceptance following its inclusion in the NPC clinical practice guidelines, which formally endorses the approach as first-line disease-modifying therapy and reinforces early intervention—critical in a disorder where 90% of VEDS patients experience events by age 40 and similar progression risks exist in NPC if untreated.
The global EAP for aramcholamol is generating significant and growing revenue, with $10.2 million in net reimbursements recorded in Q1 2026 alone, reflecting a stabilizing patient base in key territories like France where the program delivers approximately $10 million net annually post-stabilization, and the company has expanded to 122 patients across multiple geographies through compassionate use and named patient reimbursement pathways, providing a tangible proof of demand and real-world evidence that supports the ongoing EMA review of the marketing authorization application for aramcholamol in Europe, where an estimated 1,100 NPC patients reside and diagnosis rates exceed those in the U.S. due to earlier miglustat approval; this positions ZVRA to capture meaningful European revenue upon approval, with the potential to add a multi-million dollar annual revenue stream that is currently underappreciated by the market focused primarily on U.S. MyPlifer sales, especially given the orphan medicinal product designation in Europe and the company's progress in addressing the EMA's 120-day list of questions within the 90-day clock stop period, indicating regulatory advancement that could lead to approval and commercial launch in advance of expectations.
ZVRA's late-stage asset saliprolol for VEDS presents a substantial near-term catalyst that is being underestimated, as the DISCOVER Phase III trial has already enrolled 62 patients with 10 added in Q1, and the company has recorded two confirmed clinical events out of the 28 required for interim analysis, demonstrating active progression in an event-driven study for a condition with no approved therapies and approximately 7,500 U.S. patients; following the constructive FDA Type C meeting in Q1, the company is preparing for a follow-up meeting in the second half of 2026 to explore acceleration pathways, and given the lack of alternatives and the drug's mechanism as a selective adrenoceptor modulator reducing mechanical stress on arterial walls, saliprolol could secure accelerated approval or priority review based on the strength of the existing long-term European off-label use data and the trial's design, which would unlock a significant new revenue opportunity in a niche with zero competition and high unmet need, potentially transforming the company's growth profile beyond its current reliance on MyPlifer and EAP revenues.
ZVRA's MyPlifer has demonstrated a clear path to capturing the majority of the addressable NPC patient population in the U.S., with 170 prescription enrollment forms received since launch representing approximately half of the estimated 900 U.S. patients, and the company is actively expanding beyond traditional centers of excellence into community-based prescribers through its AI-driven targeting model and disease awareness campaigns, which is lowering barriers to diagnosis in an underdiagnosed disease where heterogeneity often delays identification; this strategy is already yielding new enrollments from both previously undiagnosed and newly diagnosed patients, as evidenced by the nine enrollment forms in Q1 alone, suggesting sustainable patient acquisition momentum that could drive MyPlifer U.S. net sales well beyond the current $24.6 million quarterly run rate as diagnosis rates improve and the combination therapy benefit with miglustat gains broader acceptance following its inclusion in the NPC clinical practice guidelines, which formally endorses the approach as first-line disease-modifying therapy and reinforces early intervention—critical in a disorder where 90% of VEDS patients experience events by age 40 and similar progression risks exist in NPC if untreated.
The global EAP for aramcholamol is generating significant and growing revenue, with $10.2 million in net reimbursements recorded in Q1 2026 alone, reflecting a stabilizing patient base in key territories like France where the program delivers approximately $10 million net annually post-stabilization, and the company has expanded to 122 patients across multiple geographies through compassionate use and named patient reimbursement pathways, providing a tangible proof of demand and real-world evidence that supports the ongoing EMA review of the marketing authorization application for aramcholamol in Europe, where an estimated 1,100 NPC patients reside and diagnosis rates exceed those in the U.S. due to earlier miglustat approval; this positions ZVRA to capture meaningful European revenue upon approval, with the potential to add a multi-million dollar annual revenue stream that is currently underappreciated by the market focused primarily on U.S. MyPlifer sales, especially given the orphan medicinal product designation in Europe and the company's progress in addressing the EMA's 120-day list of questions within the 90-day clock stop period, indicating regulatory advancement that could lead to approval and commercial launch in advance of expectations.
ZVRA's late-stage asset saliprolol for VEDS presents a substantial near-term catalyst that is being underestimated, as the DISCOVER Phase III trial has already enrolled 62 patients with 10 added in Q1, and the company has recorded two confirmed clinical events out of the 28 required for interim analysis, demonstrating active progression in an event-driven study for a condition with no approved therapies and approximately 7,500 U.S. patients; following the constructive FDA Type C meeting in Q1, the company is preparing for a follow-up meeting in the second half of 2026 to explore acceleration pathways, and given the lack of alternatives and the drug's mechanism as a selective adrenoceptor modulator reducing mechanical stress on arterial walls, saliprolol could secure accelerated approval or priority review based on the strength of the existing long-term European off-label use data and the trial's design, which would unlock a significant new revenue opportunity in a niche with zero competition and high unmet need, potentially transforming the company's growth profile beyond its current reliance on MyPlifer and EAP revenues.
ZVRA's U.S. MyPlifer commercialization faces persistent headwinds from payer access limitations, as only 69% of covered lives currently have access to the drug through standard formulary pathways, and while the company relies on medical exception pathways for the remainder, this process introduces variability and delay in patient onboarding, as acknowledged in the Q&A when discussing reauthorization impacts in Q1 that distorted channel inventory and complicated the assessment of true demand trends; furthermore, the company does not currently negotiate contractual rebates or discounts with payers, leaving net pricing vulnerable to standard government discounts and distribution margins, which could erode gross-to-net realization if payer scrutiny increases amid broader healthcare cost containment efforts, particularly as MyPlifer's premium pricing comes under pressure despite its clinical differentiation, and the reliance on exception pathways rather than broad formulary acceptance may limit sustainable penetration in community-based practices where administrative burden deters adoption, undermining the goal of expanding beyond centers of excellence.
The DISCOVER trial for saliprolol in VEDS is progressing slower than implied by enrollment numbers, with only 62 patients enrolled to date and just two confirmed events recorded against the 28 needed for interim analysis, suggesting a prolonged timeline to reach critical data milestones given the low event rate in a population where arterial ruptures or dissections are the primary endpoints, and while the company cites ongoing efforts to build genetic testing networks and strengthen specialist connections, the heterogeneity of VEDS presentation—similar to NPC—continues to challenge diagnosis and enrollment, as noted in the discussion of misdiagnosis cases (e.g., adult patients previously treated for MS), which prolongs the natural history study required to capture sufficient events, potentially delaying any interim readout or FDA submission well into 2027 or beyond, and thus deferring the anticipated catalyst for near-term revenue diversification that investors may be pricing into the stock based on optimistic assumptions about trial execution speed.
ZVRA's financial strength, while highlighted by the $236.8 million cash balance and debt-free status, is heavily reliant on non-recurring transactions, as the Q1 2026 net income of $37.9 million was driven by a $43.3 million one-time gain from the SDX portfolio sale, partially offset by a $10 million debt extinguishment expense, and when adjusted for these items, the core operating net income was only $11.5 million, indicating that the underlying profitability of the rare disease franchise remains modest relative to the cash balance, and with R&D expenses increasing to $4.4 million in Q1 due to third-party costs and professional fees tied to saliprolol development, and SG&A rising to $20.8 million from expanded commercial efforts, the company may face pressure to sustain operating leverage as it scales global EAP support, pursues EMA approval for aramcholamol, and advances the VEDS program, particularly if revenue growth from MyPlifer fails to accelerate sufficiently to offset these rising fixed costs, raising questions about the long-term sustainability of the current cash burn trajectory without additional near-term revenue infusions.
ZVRA's U.S. MyPlifer commercialization faces persistent headwinds from payer access limitations, as only 69% of covered lives currently have access to the drug through standard formulary pathways, and while the company relies on medical exception pathways for the remainder, this process introduces variability and delay in patient onboarding, as acknowledged in the Q&A when discussing reauthorization impacts in Q1 that distorted channel inventory and complicated the assessment of true demand trends; furthermore, the company does not currently negotiate contractual rebates or discounts with payers, leaving net pricing vulnerable to standard government discounts and distribution margins, which could erode gross-to-net realization if payer scrutiny increases amid broader healthcare cost containment efforts, particularly as MyPlifer's premium pricing comes under pressure despite its clinical differentiation, and the reliance on exception pathways rather than broad formulary acceptance may limit sustainable penetration in community-based practices where administrative burden deters adoption, undermining the goal of expanding beyond centers of excellence.
The DISCOVER trial for saliprolol in VEDS is progressing slower than implied by enrollment numbers, with only 62 patients enrolled to date and just two confirmed events recorded against the 28 needed for interim analysis, suggesting a prolonged timeline to reach critical data milestones given the low event rate in a population where arterial ruptures or dissections are the primary endpoints, and while the company cites ongoing efforts to build genetic testing networks and strengthen specialist connections, the heterogeneity of VEDS presentation—similar to NPC—continues to challenge diagnosis and enrollment, as noted in the discussion of misdiagnosis cases (e.g., adult patients previously treated for MS), which prolongs the natural history study required to capture sufficient events, potentially delaying any interim readout or FDA submission well into 2027 or beyond, and thus deferring the anticipated catalyst for near-term revenue diversification that investors may be pricing into the stock based on optimistic assumptions about trial execution speed.
ZVRA's financial strength, while highlighted by the $236.8 million cash balance and debt-free status, is heavily reliant on non-recurring transactions, as the Q1 2026 net income of $37.9 million was driven by a $43.3 million one-time gain from the SDX portfolio sale, partially offset by a $10 million debt extinguishment expense, and when adjusted for these items, the core operating net income was only $11.5 million, indicating that the underlying profitability of the rare disease franchise remains modest relative to the cash balance, and with R&D expenses increasing to $4.4 million in Q1 due to third-party costs and professional fees tied to saliprolol development, and SG&A rising to $20.8 million from expanded commercial efforts, the company may face pressure to sustain operating leverage as it scales global EAP support, pursues EMA approval for aramcholamol, and advances the VEDS program, particularly if revenue growth from MyPlifer fails to accelerate sufficiently to offset these rising fixed costs, raising questions about the long-term sustainability of the current cash burn trajectory without additional near-term revenue infusions.